Journal»Journal of the European Academy of Dermatology and Venereology
Year»1995
Loading references information
The objectives were to evaluate the efficacy, safety and tolerability of calcipotriol cream compared to betamethasone valerate cream in cases of stable plaque type of psoriasis. In a multicenter study 421 patients from 41 centers in Finland, Norway, Sweden and UK were randomized to either calcipotriol or betamethasone. The groups were well matched at baseline. Calcipotriol cream, 50 μg/g, or beta methasone cream, 1 mg/g, was applied twice daily for 8 weeks. The reduction of PASI was highly significant in both groups, 48% and 45% in the calcipotriol and the betamethasone group, respectively. There was no statistical difference between the groups. Treatment-related adverse events were more common with calcipotriol than betamethasone, however without exception of mild degree. No change in serum level of calcium was found.Calcipotriol cream is shown effective, safe and well tolerated, and equally effective as betamethasone valerate cream in the treatment of plaque type psoriasis.
The efficacy, safety and tolerability of calcipotriol cream was compared with betamethasone 17-valerate cream in the treatment of plaque-type psoriasis in a multicentre double-blind, parallel group study. Patients with stable mild-to-moderate chronic disease were randomized to treatment with either calcipotriol, 50 micrograms/g, in a cream formulation (210 patients) or betamethasone 17-valerate cream, 1 mg/g (211 patients). After a wash-out period of 2 weeks, the treatment was applied twice daily, without occlusion, for 8 weeks or to complete clearing. The severity of psoriasis was assessed using the PASI at baseline and after 4 and 8 weeks treatment. The mean percentage reduction of PASI from baseline to end of treatment was 47.8% in the calcipotriol group and 45.4% in the betamethasone group. The reduction from baseline was highly significant in both groups, but the difference between the groups was not significant. There was a difference in the reduction in thickness of the lesions in favour of calcipotriol. The investigator's as well as the patient's overall assessment of treatment response at end of treatment showed no difference between the two treatment groups. Treatment-related adverse events were more frequent with calcipotriol than betamethasone. Lesional/perilesional irritation was reported in 16% and 9% (P = 0.03), and facial irritation in 10% and 0.5% (P < 0.001), respectively. No change was found in serum levels of calcium. Calcipotriol in a cream formulation was effective, safe, well-tolerated, and equal in effect to betamethasone valerate cream.
The objectives were to evaluate the efficacy, safety and tolerability of calcipotriol cream compared to betamethasone valerate cream in cases of stable plaque type of psoriasis. In a multicenter study 421 patients from 41 centers in Finland, Norway, Sweden and UK were randomized to either calcipotriol or betamethasone. The groups were well matched at baseline. Calcipotriol cream, 50 μg/g, or beta methasone cream, 1 mg/g, was applied twice daily for 8 weeks. The reduction of PASI was highly significant in both groups, 48% and 45% in the calcipotriol and the betamethasone group, respectively. There was no statistical difference between the groups. Treatment-related adverse events were more common with calcipotriol than betamethasone, however without exception of mild degree. No change in serum level of calcium was found.Calcipotriol cream is shown effective, safe and well tolerated, and equally effective as betamethasone valerate cream in the treatment of plaque type psoriasis.
